4-[4-(5-Fluoro-2-methoxyphenyl)phenyl]-3-[(2-hydrazinyl-2-oxoacetyl)amino]butanoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 肽模拟物
• 英文名称: 4-[4-(5-Fluoro-2-methoxyphenyl)phenyl]-3-[(2-hydrazinyl-2-oxoacetyl)amino]butanoic acid
• 英文别名: 4-[4-(5-fluoro-2-methoxyphenyl)phenyl]-3-[(2-hydrazinyl-2-oxoacetyl)amino]butanoic acid
• 化学式: C₁₉H₂₀FN₃O₅
• 分子量: 389.4
• InChiKey: WEDBJLLJPNNUHP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  28
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  131
• 氢给体数：
  4
• 氢受体数：
  7

文献信息

• Substituted bisphenyl butanoic acid derivatives as NEP inhibitors with improved in vivo Efficacy
  申请人：BARNES David Weninger

  公开号：US20140228415A1

  公开（公告）日：2014-08-14

  The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein X is defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides pharmaceutical composition of the compounds of the invention and a combination of pharmacologically active agents and a compound of the invention.

  本发明提供了化合物I的化合物；或其药学上可接受的盐，其中X在此处定义。本发明还涉及一种制备本发明化合物的方法，以及其治疗用途。本发明还提供了所述化合物的药物组合物和药理活性剂的组合与所述化合物。
• SUBSTITUTED BISPHENYL BUTANOIC ACID DERIVATIVES AS NEP INHIBITORS WITH IMPROVED IN VIVO EFFICACY
  申请人：Novartis AG

  公开号：EP2956445A1

  公开（公告）日：2015-12-23
• US9102635B2
  申请人：——

  公开号：US9102635B2

  公开（公告）日：2015-08-11
• [EN] SUBSTITUTED BISPHENYL BUTANOIC ACID DERIVATIVES AS NEP INHIBITORS WITH IMPROVED IN VIVO EFFICACY<br/>[FR] DÉRIVÉS DE L'ACIDE BUTANOÏQUE BISPHÉNYLE SUBSTITUÉ UTILES EN TANT QU'INHIBITEURS DE NEP PRÉSENTANT UNE MEILLEURE EFFICACITÉ IN VIVO
  申请人：NOVARTIS AG

  公开号：WO2014126972A1

  公开（公告）日：2014-08-21

  The present invention provides a compound of formula (I); or a pharmaceutically acceptable salt thereof, wherein X is defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides pharmaceutical composition of the compounds of the invention and a combination of pharmacologically active agents and a compound of the invention.